LABORATORY RESEARCH Hematopoietic Progenitor Cell Lines with Myeloid and Lymphoid Potential Investigators showed that retroviral delivery of an estrogen-regulated form of Hoxb8 into mouse bone marrow cells can be used along with Flt3 ligand to conditionally immortalize early hematopoietic progenitor cells. [Nat Methods] Abstract HDAC3 Is Essential for DNA Replication in Hematopoietic Progenitor Cells Because Histone deacetylase 3 (HDAC3) associates with oncoproteins that drive leukemia and lymphoma, researchers engineered a conditional deletion allele in mice to explore the physiological roles of Hdac3 in hematopoiesis. [J Clin Invest] Full Article | Press Release Self-Renewal of Single Mouse Hematopoietic Stem Cells Is Reduced by JAK2V617F without Compromising Progenitor Cell Expansion Human myeloproliferative neoplasms are thought to reflect transformation of a hematopoietic stem cell (HSC) and the majority harbor an acquired V617F mutation in the JAK2 tyrosine kinase, making them a paradigm for studying the early stages of tumor establishment and progression. By using conditional knock-in mice, investigators showed that the HSC defect resulting from expression of heterozygous human JAK2V617F is both quantitative (reduced HSC numbers) and qualitative (lineage biases and reduced self-renewal per HSC). [PLoS Biol] Full Article | Press Release Runx3 Deficiency Results in Myeloproliferative Disorder in Aged Mice Investigators showed the hematopoietic phenotypes in Runx3 conditional knockout (KO) mice: while young Runx3 KO mice did not exhibit any significant hematopoietic defects, aged Runx3 KO mice developed a myeloproliferative disorder characterized by myeloid-dominant leukocytosis, splenomegaly and an increase of hematopoietic stem/progenitor cells. [Blood] Abstract An MLL-Dependent Network Sustains Hematopoiesis Researchers identified and characterized part of the mixed lineage leukemia (Mll)-dependent transcriptional network in hematopoietic stem cells with an integrated approach by using conditional loss-of-function models, genomewide expression analyses, chromatin immunoprecipitation, and functional rescue assays. [Proc Natl Acad Sci USA] Abstract | Press Release Myeloid/Microglial Driven Autologous Hematopoietic Stem Cell Gene Therapy Corrects a Neuronopathiclysosomal Disease The authors demonstrated compelling evidence of neurological disease correction using autologous myeloid driven lentiviral-hematopoietic stem cell gene therapy in mucopolysaccharidosistype IIIA mice. [Mol Ther] Abstract Organopalladium Compound 7b Targets Mitochondrial Thiols and Induces Caspase-Dependent Apoptosis in Human Myeloid Leukemia Cells Patented organopalladium compounds derived from the reaction of N,N-dimethyl-1-phenethylamine (dmpa) with [1,2-ethanebis(diphenylphosphine)] (dppe) exhibited a potent antitumor activity in vivo and in vitro in melanoma cells. Researchers showed that the cyclopalladated derivative [Pd2(R(+))C2, N-dmpa)2(μ-dppe)Cl2], named compound 7b, was highly effective to promote cell death in the K562 human leukemia cells and its mechanisms of action were investigated. [Cell Death Dis] Full Article CLINICAL RESEARCH CMV Reactivation after Allogeneic HCT and Relapse Risk: Evidence for Early Protection in Acute Myeloid Leukemia The association between CMV reactivation and relapse was evaluated in a large cohort of patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, lymphoma, and myelodysplastic syndrome who underwent allogeneic hematopoietic cell transplantation (HCT). [Blood] Abstract Outcomes of Allogeneic Hematopoietic Cell Transplant in Patients with Dyskeratosis Congenita Investigators described outcomes after allogeneic transplantation in 34 patients with dyskeratosis congenita. [Biol Blood Marrow Transplant] Abstract Outcomes and Costs of Autologous Stem Cell Mobilization with Chemotherapy Plus G-CSF vs G-CSF Alone Chemotherapy plus G-CSF (C+G) and G-CSF alone are two of the most common methods used to mobilize CD34+ cells for autologous hematopoietic SCT. In order to compare and determine the real-world outcomes and costs of these strategies, scientists performed a retrospective study of 226 consecutive patients at 11 medical centers, of whom 55% of lymphoma patients and 66% of myeloma patients received C+G. [Bone Marrow Transplant] Abstract |